118 related articles for article (PubMed ID: 10025393)
1. Early monocytopenia after chemotherapy as a risk factor for neutropenia.
Kondo M; Oshita F; Kato Y; Yamada K; Nomura I; Noda K
Am J Clin Oncol; 1999 Feb; 22(1):103-5. PubMed ID: 10025393
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic administration of granulocyte colony-stimulating factor when monocytopenia appears lessens neutropenia caused by chemotherapy for lung cancer.
Oshita F; Yamada K; Nomura I; Tanaka G; Ikehara M; Noda K
Am J Clin Oncol; 2000 Jun; 23(3):278-82. PubMed ID: 10857893
[TBL] [Abstract][Full Text] [Related]
3. Randomized study of dose or schedule modification of granulocyte colony-stimulating factor in platinum-based chemotherapy for elderly patients with lung cancer.
Oshita F; Yamada K; Nomura I; Tanaka G; Ikehara M; Noda K
Oncol Rep; 2001; 8(4):861-6. PubMed ID: 11410799
[TBL] [Abstract][Full Text] [Related]
4. A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.
Mehdi SA; Perry MC; Herndon JE; Crawford J; Young R; Graziano SL
J Interferon Cytokine Res; 1998 Aug; 18(8):623-7. PubMed ID: 9726444
[TBL] [Abstract][Full Text] [Related]
5. The change in peripheral blood monocyte count: A predictor to make the management of chemotherapy-induced neutropenia.
Ouyang W; Liu Y; Deng D; Zhou F; Xie C
J Cancer Res Ther; 2018 Sep; 14(Supplement):S565-S570. PubMed ID: 30249869
[TBL] [Abstract][Full Text] [Related]
6. The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer.
Takada M; Fukuoka M; Ariyoshi Y; Furuse K; Niitani H; Ota K; Motomiya M; Hasegawa K; Tominaga K; Kuriyama T
Cancer Chemother Pharmacol; 1992; 31(3):182-6. PubMed ID: 1281446
[TBL] [Abstract][Full Text] [Related]
7. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte-macrophage colony-stimulating factor treatment before doxorubicin and cyclophosphamide chemotherapy priming in women with early-stage breast cancer.
Kobrinsky NL; Sjolander DE; Cheang MS; Levitt R; Steen PD
J Clin Oncol; 1999 Nov; 17(11):3426-30. PubMed ID: 10550137
[TBL] [Abstract][Full Text] [Related]
10. [Effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with lung cancer].
Ohnoshi T; Ueoka H; Kodani T; Kamei H; Kimura I
Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):911-8. PubMed ID: 1693062
[TBL] [Abstract][Full Text] [Related]
11. [Effect of timing of granulocyte-colony stimulating factor administration on leukopenia induced by systemic chemotherapy in patients with non-small-cell lung cancer--multi-center randomized crossover study].
Katakami N; Hasegawa T; Umeda B; Adachi S; Ishii N; Takada Y; Tsubota N; Nakano K; Tamura R; Nakai H
Nihon Kyobu Shikkan Gakkai Zasshi; 1996 May; 34(5):520-8. PubMed ID: 8753109
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer.
Sagara Y; Sato K; Fukuma E; Higaki K; Mizutani M; Osaki A; Takano T; Tokuda Y; Ohno S; Masuda N; Suzuki M; Saeki T
Jpn J Clin Oncol; 2013 Sep; 43(9):865-73. PubMed ID: 23858037
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
[TBL] [Abstract][Full Text] [Related]
14. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
[TBL] [Abstract][Full Text] [Related]
17. Optimal schedule for administering granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer.
Soda H; Oka M; Fukuda M; Kinoshita A; Sakamoto A; Araki J; Fujino S; Itoh N; Watanabe K; Kanda T; Nakano M; Hara K
Cancer Chemother Pharmacol; 1996; 38(1):9-12. PubMed ID: 8603458
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.
Veldhuis GJ; Willemse PH; Beijnen JH; Boonstra H; Piersma H; van der Graaf WT; de Vries EG
Br J Cancer; 1997; 75(5):703-9. PubMed ID: 9043028
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D
J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727
[TBL] [Abstract][Full Text] [Related]
20. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia.
Blay JY; Chauvin F; Le Cesne A; Anglaret B; Bouhour D; Lasset C; Freyer G; Philip T; Biron P
J Clin Oncol; 1996 Feb; 14(2):636-43. PubMed ID: 8636781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
